Investing.comDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 04:29:08·⟳ 抓取 04:36:03 +6m55s·⚡ 决策 10-13 04:45:03 +9m00s·14.7 天前
Nurix Q3营收因罗氏合作确认6.53亿美元授权费而暴增，盘后冲高+8%后回落至平盘
本季利润和营收几乎全部由2026-06-08即已公告的罗氏交易一次性授权费（6.532亿美元）贡献，属于已知事件的会计确认而非新增基本面；盘后从+8%回落至约平盘显示市场已识别其一次性本质并兑现卖压。公司未下修指引、现金11亿美元、跑道至2029下半年，亦无实质利空支持做空；真正的价值催化（bexobrutideg III期数据）尚在首例给药阶段、数年后才有读数。
📄 原文Investing.com↗ 原文
Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up
Wall Street kicks off key week of bank earnings and CPI data with a mixed session Investing.com -- Nurix Therapeutics I…
不做 Nurix Therapeutics（NRIX.US）
营收/EPS暴增全部来自6月8日已官宣、Q3交割的罗氏6.532亿美元一次性授权收入，属已知利好的会计确认；盘后冲高+8%回落至平盘构成见光死，无经常性收入与新增指引支持做多；同时现金11亿美元、跑道至2029下半年、无指引下修，也无强空催化，多空皆不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Nurix三季报表面暴增（营收6.73亿、EPS 4.73美元）实为6月已官宣罗氏交易Q3交割的一次性授权收入，无经常性增量；盘后冲高+8%后回落到平盘确认见光死，无下修又不支持做空，多空皆不做。
消息传播链
- 援引公司Q3财报：营收6.731亿、调整后EPS 4.73美元；盘后一度涨近8%后转跌约2%（发稿时），公司IR原始新闻稿未在本次直接核验。市场反应:NRIX盘后高见24.00美元（较收盘22.16约+8.3%），随后回落至22.23美元（约+0.3%），量能70.8万股
关键理由
- 营收/EPS的跳变97%来自罗氏6.532亿美元一次性授权费（6月8日已公告、Q3交割），属已知利好的会计落地，非新增业绩驱动
- 盘后价格行为（高点24.00美元约+8%→22.23美元约+0.3%）显示资金借财报派发，真实催化需等III期数据
主要风险
- 若管理层在电话会披露罗氏额外近期里程碑或超预期合作扩展，盘后回落可能被修复（向上证伪）
- 临床早期负面事件或现金消耗超预期可能打破11亿美元现金支撑，但本季报未显示此类信号
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 invalidates
营收97%为罗氏一次性授权费+赛诺菲里程碑，无产品上市销售；盘后+8%回落平盘，证伪多头追涨逻辑。
检索:Nurix NRIX Q3 2026 earnings one-time license revenue Roche recurring revenue guidance 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-12 · 影响 invalidates
现金及有价证券11亿美元、跑道延长至2029下半年，无指引下修或临床失败，III期按期启动；不具备强空催化。
检索:Nurix NRIX guidance cut cash runway Phase 3 setback 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不改变标的（仅NRIX直接相关），确认方向为无edge的AVOID，不设多空仓位。
方向:无可用于统计的对齐先例；但本标的自身盘后价格行为（+8%冲高→平盘）已直接给出见光死方向证据。
涨幅量级:未做事件研究面板；一次性授权收入驱动的biotech财报不适合用常规盈利beat先例校准幅度。
形态:单标的盘后冲高回落+近20日-13%的下行轨迹，与一次性利好兑现的派发模式一致。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`nrix 罗氏 授权 653 million 财报 | nurix bexobrutideg phase 3 daybreak cll-306 sanofi milestone | nurix therapeutics nrix q3 fiscal 2026 earnings revenue roche license`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能 - web_search 成功 doubao_search · 1,219 ms
豆包搜索结果（原始查询:Nurix Therapeutics Roche collaboration deal announcement 2026 upfront license bexobrutideg；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 386 ms
{
原文全文
展开原文 · 1,806 字
Wall Street kicks off key week of bank earnings and CPI data with a mixed session
Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year. The company posted adjusted earnings per share of $4.73, compared to a loss of -$1.03 per share in the prior-year period. Shares are down 2% in after hours trading following the earnings release, though they were up nearly 8% shortly after.
The revenue surge was primarily driven by $653.2 million in license revenue from the company’s collaboration with Roche and a $10 million development milestone payment from Sanofi. During the quarter, Nurix dosed the first patient in its registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL.
"The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.
Research and development expenses for the quarter were $79.3 million, down from $86.1 million in the year-ago period, primarily due to cost sharing related to the Roche collaboration. General and administrative expenses increased to $34.4 million from $13.2 million, driven by one-time expenses associated with the Roche transaction.
The company reported cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, compared with $592.9 million as of November 30, 2025. Nurix stated this provides runway into the second half of 2029.
Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year. The company posted adjusted earnings per share of $4.73, compared to a loss of -$1.03 per share in the prior-year period. Shares are down 2% in after hours trading following the earnings release, though they were up nearly 8% shortly after.
The revenue surge was primarily driven by $653.2 million in license revenue from the company’s collaboration with Roche and a $10 million development milestone payment from Sanofi. During the quarter, Nurix dosed the first patient in its registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL.
"The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.
Research and development expenses for the quarter were $79.3 million, down from $86.1 million in the year-ago period, primarily due to cost sharing related to the Roche collaboration. General and administrative expenses increased to $34.4 million from $13.2 million, driven by one-time expenses associated with the Roche transaction.
The company reported cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, compared with $592.9 million as of November 30, 2025. Nurix stated this provides runway into the second half of 2029.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e42e4fb09c· 2026-10-13 04:45 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前